Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of a Single Intravenous Dose of CRISPR/Cas9-Edited Autologous CD34+ Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Sickle Cell Disease

NCT06287099 is registered in ClinicalTrials.gov with Bioray Laboratories as lead sponsor.

NCT NCT06287099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06287099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of a Single Intravenous Dose of CRISPR/Cas9-Edited Autologous CD34+ Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Sickle Cell Disease
Lead sponsor
Bioray Laboratories
Phase
Not applicable
Overall status
Unknown status
Start date
April 20, 2024
Completion date
May 10, 2026
Enrollment
5 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease